<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315640</url>
  </required_header>
  <id_info>
    <org_study_id>C-05-03</org_study_id>
    <secondary_id>2005-001598-93</secondary_id>
    <nct_id>NCT00315640</nct_id>
  </id_info>
  <brief_title>Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation</brief_title>
  <official_title>A Study of the Safety and Efficacy of Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot
      when administered for the treatment of elevated IOP following treatment with steroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in IOP at Week 4 from Baseline</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>Anecortave Acetate 3 mg Depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anecortave Acetate 15 mg Depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anecortave Acetate 30 mg Depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anecortave Acetate Vehicle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 6 mg/mL</intervention_name>
    <description>One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye</description>
    <arm_group_label>Anecortave Acetate 3 mg Depot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Suspension Depot, 30 mg/mL</intervention_name>
    <description>One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye</description>
    <arm_group_label>Anecortave Acetate 15 mg Depot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 60 mg/mL</intervention_name>
    <description>One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye</description>
    <arm_group_label>Anecortave Acetate 30 mg Depot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anecortave Acetate Vehicle</intervention_name>
    <description>One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye</description>
    <arm_group_label>Anecortave Acetate Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either gender

          -  18 years of age or older

          -  IOP elevation caused by steroid usage

          -  Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Under 18 years of age

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Landry</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Paulo</name>
      <address>
        <city>San Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayamon</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2006</study_first_submitted>
  <study_first_submitted_qc>April 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2006</study_first_posted>
  <disposition_first_submitted>November 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 28, 2012</disposition_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elevated IOP due to intravitreal triamcinolone therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anecortave</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

